ICU admission, vancomycin concentration predicted acute kidney injuryHealioAn initial vancomycin serum trough concentration of at least 15 mg/L and admission to the ICU can predict acute kidney injury among children, according to recent study results p…
Researchers describe 1 mechanism that favors rejection in transplantation of … – Science Codex
Science CodexResearchers describe 1 mechanism that favors rejection in transplantation of …Science CodexIn that vein, the group Cristina Costa works in xenotransplantation research of cartilage cells (chondrocytes) pig in human joints that have suffe…
Sonia Gandhi congratulates India's first liver transplant recipient – Parda Phash
Parda Phash |
Sonia Gandhi congratulates India’s first liver transplant recipient
Parda Phash … enjoys meals, plays football and wants to become a doctor to save lives. Sanjay’s success helped establish liver transplantation in India,” said Anupam Sibal, senior paediatric gastroenterologist in the hospital. Babulal Nagar’s judicial custody … Sonia Gandhi felicitates liver transplant recipientBusiness Standard |
Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS … – RTT News
|
Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS …
RTT News Boston Scientific Corp. (BSX: Quote) said Monday that it has received U.S. Food and Drug Administration or FDA approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company’s next-generation durable … Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street Journal Boston Scientific Receives FDA Approval For Promus Premier Everolimus …Benzinga FDA approves next-generation EESHealio Forbes –MedCity News –Worcester Business Journal all 10 news articles » |
Boston Scientific Corporation : Boston Scientific Receives FDA Approval For … – 4-traders (press release)
|
Boston Scientific Corporation : Boston Scientific Receives FDA Approval For …
4-traders (press release) 25, 2013/PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER™ Everolimus-Eluting … |
Long term gene therapy beneficial for advanced heart failure patients – The Almagest
The AlmagestLong term gene therapy beneficial for advanced heart failure patientsThe Almagest(The Almagest) According to a research conducted at Icahn School of Medicine at Mount Sinai suggested that the long-term benefits of a single dose of the given…
Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS … – NASDAQ
|
Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS …
NASDAQ (RTTNews.com) – Boston Scientific Corp. ( BSX ) said Monday that it has received U.S. Food and Drug Administration or FDA approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company’s next-generation … Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street Journal FDA approves next-generation EESHealio BSX scores FDA device approval for drug-eluting stent for coronary artery …MedCity News Worcester Business Journal all 10 news articles » |
Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure … – PharmiWeb.com (press release)
|
Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure …
PharmiWeb.com (press release) Given that over 80% of heart failure patients are 65 years of age or older1 it’s no wonder then that according to the American Heart Association the number of Americans with heart failure is expected to jump from just over 5 million today to 8 million … |
Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus … – Wall Street Journal
Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street JournalNATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) ha…
Arzerra Gets a New Boxed Warning – Legal Examiner
Arzerra Gets a New Boxed WarningLegal ExaminerThe anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) recently got an upgrade to their boxed warning labels, adding information about the potential risk for reactivation of hepatitis B infectio…